GlaxoSmithKline

GSK's depemokimab reduced serious asthma attacks by 54% and hospitalizations by 72% in year-long trials, positioning it as a key growth driver with potential annual sales of £3 billion. The drug requires injections every six months, less frequent than competitors, and is being tested for other type 2 inflammatory conditions.

SWIFT-1 and SWIFT-2 phase III data show depemokimab significantly reduces asthma exacerbations over 52 weeks versus placebo. Depemokimab, an ultra-long-acting biologic, administered once every six months, sustained suppression of type 2 inflammation, a key driver of asthma attacks and hospitalisations. Data published in the New England Journal of Medicine.

Depemokimab reduces severe asthma attacks by over 50% and hospitalizations by 72% in phase 3 trials, published in The New England Journal of Medicine. Administered twice yearly, it targets IL-5 to inhibit type 2 inflammation, offering a dosing schedule beneficial to patients managing multiple therapies.

The article contains a PDF file structure with metadata and viewer preferences.

GSK reports positive MATINEE Phase 3 results for Nucala in COPD, showing significant reduction in exacerbations. Nucala targets IL-5 and is not yet approved for COPD globally.

AstraZeneca completed its clinical program for a new inhaler propellant with 99.9% lower Global Warming Potential (GWP), marking a significant step in reducing the environmental impact of respiratory medicines. This propellant, HFO-1234ze, will be used in Breztri/Trixeo Aerosphere, a COPD therapy, with regulatory filings planned for Europe, the UK, and China by end of 2024. This aligns with AstraZeneca's Ambition Zero Carbon strategy to cut its carbon footprint by 50% by 2030.

GSK’s long-acting asthma treatment, depemokimab, reduced serious attacks by 54% and hospitalizations/ER visits by 72% in Phase III trials. Despite missing secondary endpoints, the drug’s primary goal of reducing exacerbations was achieved. Depemokimab, an anti-IL-5 therapy, is part of GSK’s planned 12 major product launches, expected to generate £38 billion by 2031, with peak sales of £3 billion. Administered twice yearly, it aims to address unmet needs in severe asthma treatment.

AstraZeneca completed clinical studies for a new inhaler propellant, HFO-1234ze, reducing greenhouse gas emissions by 99.9%. Breztri, a COPD therapy, will be the first to transition, with regulatory submissions expected in Europe, the UK, and China by end of 2024. This aligns with AstraZeneca's Ambition Zero Carbon strategy.

GSK's phase III trial MATINEE showed Nucala (mepolizumab) significantly reduced COPD exacerbations in patients with type 2 inflammation. Nucala targets IL-5, key in type 2 inflammation, and preliminary safety results align with known profiles. Full results to be presented at a future scientific congress.